This site uses cookies, including third-party cookies, that help us to provide and improve our services.

Privacy Policy
- Global Locations -
Headquarters
Future Market Insights, Inc.
Christiana Corporate, 200 Continental Drive, Suite 401, Newark, Delaware - 19713, United States
T: +1-845-579-5705
MEA
Market Access DMCC
1602-6 Jumeirah Bay X2 Tower, Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates
Americas
Future Market Insights
616 Corporate Way, Suite 2-9018,
Valley Cottage, NY 10989,
United States
T: +1-347-918-3531
Europe
Future Market Insights
3rd Floor, 207 Regent Street,
London W1B 3HH
United Kingdom
T: + 44 (0) 20 8123 9659
D: +44 (0) 20 3287 4268
APAC
Future Market Insights
Office No. 401-A, 4th Floor,
VANTAGE 9, S.No. 36/1/1,
Baner, Pune 411045 India

Antibody Therapy Market

Market Insights on Antibody Therapy covering sales outlook, demand forecast & up-to-date key trends

Antibody Therapy Market by Type (Monoclonal Antibodies (Oncology, Autoimmune Disease, Infectious Disease, Other), Antibody Drug Conjugates), End User (Hospitals, Specialty Centers, Others) & Region - Forecast 2022 - 2032

Antibody Therapy Market Outlook (2022-2032)

[333 Pages Report]  The global antibody therapy market is expected to reach US$ 727.78 Bn in 2032, with a favorable rate of 13.2% during the forecast period.

"The availability of a robust antibody therapy pipeline increases the company's chances of achieving higher market revenue."

As novel medicines and pharmaceuticals for treating diseases are licensed, the market for antibody therapy is growing. The increasing need for targeted pharmacological therapy and technological advancements are boosting the antibody therapy market.

Over the forecast period, the worldwide antibodies market will be driven by rising cancer and other chronic disease prevalence, rising regulatory approvals and launch of medicines, and rising research partnerships to create a robust therapeutic pipeline.

Attributes

Details

Antibody Therapy Market Size (2027)

US$ 248.9 Bn

Antibody Therapy Market Size CAGR (2022-2032)

13.2%

Antibody Therapy Market Attraction

Research and development in developing novel medicines to offer favourable opportunities.

How COVID-19 Impacts the Antibody Therapy Market?

COVID-19 significantly influenced the global economy, affecting all nations by disrupting activities in every industry, regardless of size. The rising prevalence of COVID-19 patients influenced the healthcare industry. 

While COVID-19's impact has been primarily unfavorable in some sectors, the antibody therapy industry has gained significant traction due to a surge in demand for COVID-19 therapeutic development.

 Several firms have accelerated their research and development for COVID diagnostics and treatments. Anti-SARS-CoV-2 mAb and other antibody therapies are used to treat mild to moderate cases of SARS.

COVID-19 infection received emergency use authorizations (EUAs) from the FDA and other agencies in various countries. Sotrovimab, casirivimab plus, and other EUA drugs were utilized during the epidemic.

COVID-19 is being treated using the advancement of monoclonal antibodies. Several monoclonal antibodies have demonstrated the ability to maintain an action against various viral types. Rapid product approvals for COVID-19 treatment have aided in establishing the antibody therapy sector during the pandemic. As a result, COVID-19 is expected to impact the antibody treatment industry positively.

Customize this Report

Let us know your requirement to get
100% FREE customization

What Contributes to the Growth of the Antibody Therapy Market?

“Owing to the strong demand for antibody therapy, the government and key market companies have greatly expanded R & D spending. As a result, the operation moves to a larger size.”

Strong market growth is projected due to government backing for the launch of new treatments. The rising frequency of cancer and other chronic diseases is one of the primary factors driving the global monoclonal antibodies market.

Additionally, increasing regulatory approvals and the debut of new medicines are complementing market growth. The global cancer risk is rapidly increasing, and more secure clinical treatment is being sought over traditional methods. 

Monoclonal antibodies may provide advantages, such as recognizing and eliminating a typical cell directly, suppressing cancer cell development, and delivering radioactive particles or chemo medicines to specific cells, reducing the danger of drug side effects while enhancing immune system function.

What are Obstacles for the Antibody Therapy Market Players?

The results of screening and clinical tests are influenced by antibody variation. The development process is a lengthy and challenging task. The technology necessitates huge bioreactors and filtration systems for antibody synthesis, which hinders the worldwide antibody treatment industry.

The market's expansion may be hampered by high costs and tight regulatory requirements that result in a protracted approval process.

Sabyasachi Ghosh
Principal Consultant
LinkedIn
Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Talk to Analyst

What are the Trends followed by the Antibody Therapy Market?

"Rising governmental spending in cancer research and technology development may open up new potential for the worldwide antibody therapy market to expand."

The healthcare industry is growing at a breakneck speed. The antibody therapy market is experiencing rapid growth due to these advances. On the other hand, more medication market development may be able to help. 

Antibody treatment alternatives are exploding. In the forecast period, this may have an impact on the overall demand for antibody medication therapy. It can also lead to a plethora of replacements.

The FDA approved Amgen's Repatha (evolocumab) in September 2021 to treat heterozygous familial hypercholesterolemia (HeFH) patients aged 10 and up. Patients suffering from HeFH will benefit from this approval. Seagen Inc. and Astellas Pharma Inc. also announced FDA clearance of PADCEV in the United States in September 2021. 

PADCEV is an ADC-approved medication for urothelial cancer patients with locally progressed or metastatic disease. Antibody therapy is projected to expand in popularity in the future due to continual product approvals in both developing and established countries.

Antibody treatment alternatives are exploding. In the forecast period, this may have an impact on the overall demand for antibody medication therapy. It can also lead to a plethora of replacements.

 In addition, the adverse effects of antibody therapy can inhibit growth. Furthermore, genetic treatment is expensive. A combination of replica cells is also used in antibody therapy. It is possible to target and eliminate dangerous cells in the body. This one-of-a-kind procedure is pricey. As a result, the market for antibody therapy is shrinking.

Comparative View of Adjacent Antibody Therapy Market

Antibody Therapy Market:

Attributes

Antibody Therapy Market

CAGR (2022 - 2032)

13.2%

Market Value (2026)

US$ 345.74 Mn

Growth Factor

Globally, the prevalence of chronic and infectious diseases is increasing, as are research and development activities.

Opportunity

The biologics business is booming.

Antibody treatment is becoming more widely used which is expected to open many horizons for the antibody therapy market.

Key Trends

Fast product approvals for COVID-19 treatment have aided the establishment of the antibody therapy sector during the epidemic.

Custom Antibody Market:

Attributes

Custom Antibody Market

CAGR (2022 - 2032)

10.6%

Market Value (2026)

US$ 652 Mn

Growth Factor

A growth in research effort, particularly in the life sciences industry, as well as increased industry-academia partnership

Opportunity

The rising need for protein therapies and personalized medicine, as well as the discovery of newly designed proteins, are projected to create new opportunities.

Key Trends

Concerns over the quality of catalogue antibodies, as well as the growing antibody therapeutics pipeline, are projected to propel the market ahead.

Research Antibodies & Reagents Market:

Attributes

Research Antibodies & Reagents Market

CAGR (2022 - 2032)

6.7%

Market Value (2026)

US$ 14.9 Bn

Growth Factor

Proteomics and genomics research is booming, and high-quality antibodies are in high demand for research repeatability.

Opportunity

Because of the region's diverse healthcare markets, the Asia Pacific region is likely to offer substantial growth prospects to market players in the coming years.

Key Trends

In the life sciences industry, R&D activity and spending are expanding which provides a high growing opportunity for the market.

The rising prevalence of cancer and its high mortality rate has increased the need for effective and tailored medicines, such as antibody therapy. Antibody-based treatments have evolved technologically by targeting tumor antigens and increasing immune cells' anti-tumor capabilities.

Furthermore, the antibody therapy market is predicted to develop due to rapid product advancement and technologies for cancer treatment. Antibody therapy is a focused, therapeutic intervention that involves using a concentrated or monoclonal antibody to treat diseases such as cancer, infectious disorders, autoimmune diseases, and others.

Antibodies bind to a specific antigen, which activates or inhibits a series of biological responses, including cancer development inhibition, immune system activation, and many more. During the forecast period, the market for antibody therapy will rise at a steady pace.

The market has grown dramatically as a result of next-generation genomic sequencing. However, low demand in underdeveloped areas can limit market demand. In the antibody therapy market, the high cost of treatment is also a disadvantage.

Key players who have exited the market are implementing cost-cutting measures. In the coming years, antibody therapy is projected to become more affordable and accessible. In addition, the comprehensive research projects will result in new monoclonal antibody therapy product introductions. Antibodies have a robust therapeutic pipeline, resulting in a rapid growth rate.

Antibody therapies are less well-known in developing countries. A restraining element is a low demand for monoclonal antibodies in developing countries. The investments are at a low point in the market. As a result, the market may experience a downward trend.

The positive indication from regulatory bodies to enter biosimilars of already available antibody therapies is also boosting market expansion. As a result, during the forecast period of 2021-2028, this is expected to steer the antibody therapy market expansion.

This research provides a comprehensive overview of antibody therapy utilized in the pharmaceutical and biopharmaceutical industries. This report examines and evaluates antibody therapeutic uses in human medicine.

Become a MarketNgage Insider

An unified Market Research Subscription Platform, built for today’s disparate research needs.

Which Segment has the Highest Growth Potential in the Antibody Therapy Market?

Monoclonal antibodies and antibody-drug conjugates are the two antibodies used in antibody therapy. Oncology, autoimmune diseases, infectious illnesses, and other diseases comprise the monoclonal antibodies industry.

Due to the increasing use of monoclonal antibodies (mAbs) to treat different diseases, such as cancer, infection, genetic diseases, and others, the monoclonal antibodies segment is predicted to grow at a 12.9% CAGR through 2028.

As biologic products, mAbs generate various immune-mediated reactions and responses, increasing the therapy's efficacy.

What Leads to the High Demand for the Hospital End User Segment?

The antibody treatment market is divided into hospitals, specialty centers, and other end-users depending on end-use. The hospital segment had more than 42% market share in 2021. Due to guidelines, availability, and accessibility, increasing the number of people seeking treatment in hospitals is expected to boost the market growth.

Hospitals provide:

  • Advanced therapy.
  • Quick access to advanced care.
  • Post-treatment monitoring.
  • The presence of competent personnel all in one location.

These factors combine to drive patients' preference for hospitals, boosting antibody therapy market growth over the forecast timeframe.

What is the Segmentation Outlook for the Antibody Therapy Market?

Due to key players' increased investment in innovative antibody treatment development, the North American antibody therapy market maintained a 49.1% share in 2021. As a result of the rising need for targeted medications in the region, clinical studies have increased, contributing to the market's overall growth.

The market is anticipated to continue to be dominated by North America. Demand for antibody therapy is likely to be high, resulting in high growth. Furthermore, the region's advanced healthcare infrastructure and high healthcare spending are likely to boost the regional market growth.

Many patients are drawn to the therapy by low-cost treatments. In addition, the high prevalence of cancer fuels a massive demand for monoclonal antibody therapy. Antibody treatment is in high demand in this area. With the highest share, Asia Pacific is the next largest region.

The growth of aging populations increases chronic illness rates. This ultimately creates a positive impact on the antibody therapy market. In addition, Europe is a fast-growing key participant with a lot of potentials. Europe has a high rate of investment, research, and expansion.

What are the Competitive Landscape of the Antibody Therapy Market?

The fresh entry of significant players, on the other hand, may enhance competition. In addition, significant strategies in the competitive environment include expansion, acquisitions, partnerships, mergers, and acquisitions.

In the approaching years, this market will invest heavily in research and development to strengthen its position in the antibody industry and help them expand into big players.

Major market players are Bristol-Myers Squibb, GlaxoSmithKline plc, Takeda Pharmaceuticals, Eli Lilly and Company, Merck & Co, Inc., Seagen, Johnson & Johnson, Novartis AG, Regeneron Pharmaceuticals, F. Hoffmann-La Roche Ltd., Merck & Co, IncSeagen.

  • TEZSPIRE (tezepelumab-ekko) was approved and made available by Amgen and AstraZeneca in January 2022 to treat severe asthma. The FDA's approval of this medicine will allow the corporation to expand its product line and generate significant income.
  • Regeneron received an Emergency Use Authorization (EUA) from the US Food and Drug Administration in November 2020 for its COVID-19 antibody combination casirivimab and imdevimab. This approval has boosted its revenue generation and helped it gain considerable market share.

Key Segments

By Type:

  • Monoclonal Antibodies
    • Oncology, Autoimmune Disease
    • Infectious Disease
    • Other
  • Antibody Drug Conjugates

By End User:

  • Hospitals
  • Speciality Centers
  • Others

By Region:

  • North America
  • Latin America
  • Europe
  • Asia Pacific
  • Middle East and Africa

Frequently Asked Questions

The antibody therapy market is estimated to record a 13.2% CAGR during the forecast period.

The projected value of the antibody therapy market is expected to be US$ 727.78 Bn by 2032.

The global antibody therapy market was valued at US$ 186 Bn in 2021.

Based on the end user, the hospital segment accounts for the largest revenue share.

North America is growing at the highest CAGR during the forecast period.

Table of Content

1. Executive Summary

    1.1. Global Market Outlook 

    1.2. Summary of Statistics

    1.3. Key Market Characteristics & Attributes

    1.4. Fact.MR Analysis and Recommendations

2. Market Overview

    2.1. Market Coverage / Taxonomy 

    2.2. Market Definition / Scope / Limitations

3. Market Risks and Trends Assessment 

    3.1. Risk Assessment 

        3.1.1. COVID-19 Crisis and Impact on Antibody Therapy Demand

        3.1.2. COVID-19 Impact Benchmark with Previous Crisis 

        3.1.3. Impact on Market Value (US$ Mn)

        3.1.4. Assessment by Key Countries

        3.1.5. Assessment by Key Market Segments

        3.1.6. Action Points and Recommendation for Suppliers

    3.2. Key Trends Impacting the Market

    3.3. Formulation and Product Development Trends

4. Market Background and Foundation Data Points 

    4.1. Global Protective Coatings Market (US$ Mn)

    4.2. Antibody Therapy Market Opportunity Assessment (US$ Mn)

        4.2.1. Total Available Market

        4.2.2. Serviceable Addressable Market

        4.2.3. Serviceable Obtainable Market

    4.3. Market Scenario Forecast 

        4.3.1. Demand in optimistic Scenario

        4.3.2. Demand in Likely Scenario

        4.3.3. Demand in Conservative Scenario 

    4.4. Investment Feasibility Analysis 

        4.4.1. Investment in Established Markets

            4.4.1.1. In Short Term

            4.4.1.2. In Long Term

        4.4.2. Investment in Emerging Markets

            4.4.2.1. In Short Term

            4.4.2.2. In Long Term

    4.5. Forecast Factors - Relevance & Impact 

        4.5.1. Top Companies Historical Growth

        4.5.2. Global Protective Coatings Market Growth

        4.5.3. Antibody Therapy Adoption Rate, By Country

    4.6. Market Dynamics 

        4.6.1. Market Driving Factors and Impact Assessment

        4.6.2. Prominent Market Challenges and Impact Assessment

        4.6.3. Antibody Therapy Market Opportunities

        4.6.4. Prominent Trends in the Global Market & Their Impact Assessment

5. Key Success Factors 

    5.1. Manufacturers’ Focus on Low Penetration High Growth Markets

    5.2. Banking on with Segments High Incremental Opportunity

    5.3. Peer Benchmarking 

6. Global Antibody Therapy Market Demand Analysis 2015-2021 and Forecast, 2022-2032

    6.1. Historical Market Analysis, 2015-2021

    6.2. Current and Future Market Projections, 2022-2032

    6.3. Y-o-Y Growth Trend Analysis

7. Global Antibody Therapy Market Value Analysis 2015-2021 and Forecast, 2022-2032

    7.1. Historical Market Value (US$ Mn) Analysis, 2015-2021

    7.2. Current and Future Market Value (US$ Mn) Projections, 2022-2032

        7.2.1. Y-o-Y Growth Trend Analysis

        7.2.2. Absolute $ Opportunity Analysis

8. Global Antibody Therapy Market Analysis 2015-2021 and Forecast 2022-2032, By Type

    8.1. Introduction / Key Findings

    8.2. Historical Market Size (US$ Mn) Analysis By Type, 2015-2021

    8.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Type, 2022-2032

        8.3.1. Monoclonal Antibodies (mAbs)

            8.3.1.1. Oncology

            8.3.1.2. Autoimmune Diseases

            8.3.1.3. Infectious Diseases

            8.3.1.4. Others

        8.3.2. Antibody-drug Conjugates (ADCs)

    8.4. Market Attractiveness Analysis By Type

9. Global Antibody Therapy Market Analysis 2015-2021 and Forecast 2022-2032, By End-use

    9.1. Introduction / Key Findings

    9.2. Historical Market Size (US$ Mn) Analysis By End-use, 2015-2021

    9.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By End-use, 2022-2032

        9.3.1. Hospitals

        9.3.2. Specialty Centers

        9.3.3. Others

    9.4. Market Attractiveness Analysis By End-use

10. Global Antibody Therapy Market Analysis 2015-2021 and Forecast 2022-2032, By Region

    10.1. Introduction

    10.2. Historical Market Size (US$ Mn) Analysis By Region, 2015-2021

    10.3. Current Market Size (US$ Mn) & Analysis and Forecast By Region, 2022-2032

        10.3.1. North America

        10.3.2. Latin America

        10.3.3. Europe

        10.3.4. Asia Pacific 

        10.3.5. Middle East and Africa (MEA)

    10.4. Market Attractiveness Analysis By Region

11. North America Antibody Therapy Market Analysis 2015-2021 and Forecast 2022-2032

    11.1. Introduction

    11.2. Pricing Analysis

    11.3. Historical Market Value (US$ Mn) Trend Analysis By Market Taxonomy, 2015-2021

    11.4. Market Value (US$ Mn) & Forecast By Market Taxonomy, 2022-2032

        11.4.1. By Country

            11.4.1.1. U.S.

            11.4.1.2. Canada

            11.4.1.3. Rest of North America

        11.4.2. By Type

        11.4.3. By End-use

    11.5. Market Attractiveness Analysis

        11.5.1. By Country

        11.5.2. By Type

        11.5.3. By End-use

12. Latin America Antibody Therapy Market Analysis 2015-2021 and Forecast 2022-2032

    12.1. Introduction

    12.2. Pricing Analysis

    12.3. Historical Market Value (US$ Mn) Trend Analysis By Market Taxonomy, 2015-2021

    12.4. Market Value (US$ Mn) & Forecast By Market Taxonomy, 2022-2032

        12.4.1. By Country

            12.4.1.1. Brazil

            12.4.1.2. Mexico

            12.4.1.3. Rest of Latin America

        12.4.2. By Type

        12.4.3. By End-use

    12.5. Market Attractiveness Analysis

        12.5.1. By Country

        12.5.2. By Type

        12.5.3. By End-use

13. Europe Antibody Therapy Market Analysis 2015-2021 and Forecast 2022-2032

    13.1. Introduction

    13.2. Pricing Analysis

    13.3. Historical Market Value (US$ Mn) Trend Analysis By Market Taxonomy, 2015-2021

    13.4. Market Value (US$ Mn) & Forecast By Market Taxonomy, 2022-2032

        13.4.1. By Country

            13.4.1.1. Germany

            13.4.1.2. France

            13.4.1.3. U.K.

            13.4.1.4. Italy

            13.4.1.5. Benelux

            13.4.1.6. Nordic Countries

            13.4.1.7. Rest of Europe

        13.4.2. By Type

        13.4.3. By End-use

    13.5. Market Attractiveness Analysis

        13.5.1. By Country

        13.5.2. By Type

        13.5.3. By End-use

14. Asia Pacific Antibody Therapy Market Analysis 2015-2021 and Forecast 2022-2032

    14.1. Introduction

    14.2. Pricing Analysis

    14.3. Historical Market Value (US$ Mn) Trend Analysis By Market Taxonomy, 2015-2021

    14.4. Market Value (US$ Mn) & Forecast By Market Taxonomy, 2022-2032

        14.4.1. By Country

            14.4.1.1. China

            14.4.1.2. Japan

            14.4.1.3. South Korea

            14.4.1.4. Rest of Asia Pacific

        14.4.2. By Type

        14.4.3. By End-use

    14.5. Market Attractiveness Analysis

        14.5.1. By Country

        14.5.2. By Type

        14.5.3. By End-use

15. Middle East and Africa Antibody Therapy Market Analysis 2015-2021 and Forecast 2022-2032

    15.1. Introduction

    15.2. Pricing Analysis

    15.3. Historical Market Value (US$ Mn) Trend Analysis By Market Taxonomy, 2015-2021

    15.4. Market Value (US$ Mn) & Forecast By Market Taxonomy, 2022-2032

        15.4.1. By Country

            15.4.1.1. GCC Countries

            15.4.1.2. South Africa

            15.4.1.3. Turkey

            15.4.1.4. Rest of Middle East and Africa

        15.4.2. By Type

        15.4.3. By End-use

    15.5. Market Attractiveness Analysis

        15.5.1. By Country

        15.5.2. By Type

        15.5.3. By End-use

16. Key Countries Antibody Therapy Market Analysis 2015-2021 and Forecast 2022-2032

    16.1. Introduction

        16.1.1. Market Value Proportion Analysis, By Key Countries

        16.1.2. Global Vs. Country Growth Comparison

    16.2. US Antibody Therapy Market Analysis

        16.2.1. Value Proportion Analysis by Market Taxonomy

        16.2.2. Value & Analysis and Forecast by Market Taxonomy, 2015-2032

            16.2.2.1. By Type

            16.2.2.2. By End-use

    16.3. Canada Antibody Therapy Market Analysis

        16.3.1. Value Proportion Analysis by Market Taxonomy

        16.3.2. Value & Analysis and Forecast by Market Taxonomy, 2015-2032

            16.3.2.1. By Type

            16.3.2.2. By End-use

    16.4. Mexico Antibody Therapy Market Analysis

        16.4.1. Value Proportion Analysis by Market Taxonomy

        16.4.2. Value & Analysis and Forecast by Market Taxonomy, 2015-2032

            16.4.2.1. By Type

            16.4.2.2. By End-use

    16.5. Brazil Antibody Therapy Market Analysis

        16.5.1. Value Proportion Analysis by Market Taxonomy

        16.5.2. Value & Analysis and Forecast by Market Taxonomy, 2015-2032

            16.5.2.1. By Type

            16.5.2.2. By End-use

    16.6. Germany Antibody Therapy Market Analysis

        16.6.1. Value Proportion Analysis by Market Taxonomy

        16.6.2. Value & Analysis and Forecast by Market Taxonomy, 2015-2032

            16.6.2.1. By Type

            16.6.2.2. By End-use

    16.7. France Antibody Therapy Market Analysis

        16.7.1. Value Proportion Analysis by Market Taxonomy

        16.7.2. Value & Analysis and Forecast by Market Taxonomy, 2015-2032

            16.7.2.1. By Type

            16.7.2.2. By End-use

    16.8. Italy Antibody Therapy Market Analysis

        16.8.1. Value Proportion Analysis by Market Taxonomy

        16.8.2. Value & Analysis and Forecast by Market Taxonomy, 2015-2032

            16.8.2.1. By Type

            16.8.2.2. By End-use

    16.9. BENELUX Antibody Therapy Market Analysis

        16.9.1. Value Proportion Analysis by Market Taxonomy

        16.9.2. Value & Analysis and Forecast by Market Taxonomy, 2015-2032

            16.9.2.1. By Type

            16.9.2.2. By End-use

    16.10. UK Antibody Therapy Market Analysis

        16.10.1. Value Proportion Analysis by Market Taxonomy

        16.10.2. Value & Analysis and Forecast by Market Taxonomy, 2015-2032

            16.10.2.1. By Type

            16.10.2.2. By End-use

    16.11. Nordic Countries Antibody Therapy Market Analysis

        16.11.1. Value Proportion Analysis by Market Taxonomy

        16.11.2. Value & Analysis and Forecast by Market Taxonomy, 2015-2032

            16.11.2.1. By Type

            16.11.2.2. By End-use

    16.12. China Antibody Therapy Market Analysis

        16.12.1. Value Proportion Analysis by Market Taxonomy

        16.12.2. Value & Analysis and Forecast by Market Taxonomy, 2015-2032

            16.12.2.1. By Type

            16.12.2.2. By End-use

    16.13. Japan Antibody Therapy Market Analysis

        16.13.1. Value Proportion Analysis by Market Taxonomy

        16.13.2. Value & Analysis and Forecast by Market Taxonomy, 2015-2032

            16.13.2.1. By Type

            16.13.2.2. By End-use

    16.14. South Korea Antibody Therapy Market Analysis

        16.14.1. Value Proportion Analysis by Market Taxonomy

        16.14.2. Value & Analysis and Forecast by Market Taxonomy, 2015-2032

            16.14.2.1. By Type

            16.14.2.2. By End-use

    16.15. GCC Countries Antibody Therapy Market Analysis

        16.15.1. Value Proportion Analysis by Market Taxonomy

        16.15.2. Value & Analysis and Forecast by Market Taxonomy, 2015-2032

            16.15.2.1. By Type

            16.15.2.2. By End-use

    16.16. South Africa Antibody Therapy Market Analysis

        16.16.1. Value Proportion Analysis by Market Taxonomy

        16.16.2. Value & Analysis and Forecast by Market Taxonomy, 2015-2032

            16.16.2.1. By Type

            16.16.2.2. By End-use

    16.17. Turkey Antibody Therapy Market Analysis

        16.17.1. Value Proportion Analysis by Market Taxonomy

        16.17.2. Value & Analysis and Forecast by Market Taxonomy, 2015-2032

            16.17.2.1. By Type

            16.17.2.2. By End-use

        16.17.3. Competition Landscape and Player Concentration in the Country

17. Market Structure Analysis

    17.1. Market Analysis by Tier of Companies 

    17.2. Market Concentration

    17.3. Market Share Analysis of Top Players

    17.4. Market Presence Analysis

        17.4.1. By Regional footprint of Players

        17.4.2. Product footprint by Players

18. Competition Analysis

    18.1. Competition Dashboard

    18.2. Competition Benchmarking

    18.3. Competition Deep Dive 

        18.3.1. F. Hoffmann-La Roche Ltd

            18.3.1.1. Overview

            18.3.1.2. Product Portfolio

            18.3.1.3. Sales Footprint

            18.3.1.4. Strategy Overview

        18.3.2. AbbVie Inc

            18.3.2.1. Overview

            18.3.2.2. Product Portfolio

            18.3.2.3. Sales Footprint

            18.3.2.4. Strategy Overview

        18.3.3. Amgen Inc

            18.3.3.1. Overview

            18.3.3.2. Product Portfolio

            18.3.3.3. Sales Footprint

            18.3.3.4. Strategy Overview

        18.3.4. Bristol-Myers Squibb Company

            18.3.4.1. Overview

            18.3.4.2. Product Portfolio

            18.3.4.3. Sales Footprint

            18.3.4.4. Strategy Overview

        18.3.5. Johnson & Johnson Services, Inc

            18.3.5.1. Overview

            18.3.5.2. Product Portfolio

            18.3.5.3. Sales Footprint

            18.3.5.4. Strategy Overview

        18.3.6. Seagen

            18.3.6.1. Overview

            18.3.6.2. Product Portfolio

            18.3.6.3. Sales Footprint

            18.3.6.4. Strategy Overview

        18.3.7. Merck & Co. Inc

            18.3.7.1. Overview

            18.3.7.2. Product Portfolio

            18.3.7.3. Sales Footprint

            18.3.7.4. Strategy Overview

        18.3.8. Regeneron Pharmaceuticals Inc

            18.3.8.1. Overview

            18.3.8.2. Product Portfolio

            18.3.8.3. Sales Footprint

            18.3.8.4. Strategy Overview

        18.3.9. Novartis AG

            18.3.9.1. Overview

            18.3.9.2. Product Portfolio

            18.3.9.3. Sales Footprint

            18.3.9.4. Strategy Overview

        18.3.10. AstraZeneca

            18.3.10.1. Overview

            18.3.10.2. Product Portfolio

            18.3.10.3. Sales Footprint

            18.3.10.4. Strategy Overview

19. Assumptions and Acronyms Used

20. Research Methodology

Customize this Report

Let us know your requirement to get
100% FREE customization

List of Tables

Table 1: Global Antibody Therapy Market Value (US$ Mn), By Type, 2015 – 2021

Table 2: Global Antibody Therapy Market Value (US$ Mn), By Type, 2022 – 2032

Table 3: Global Antibody Therapy Market Value (US$ Mn), By End-use, 2015 – 2021

Table 4: Global Antibody Therapy Market Value (US$ Mn), By End-use, 2022 – 2032

Table 5: Global Antibody Therapy Market, By Region, 2015 – 2021

Table 6: Global Antibody Therapy Market, By Region, 2022 – 2032

Table 7: North America Antibody Therapy Market Value (US$ Mn), By Type, 2015 – 2021

Table 8: North America Antibody Therapy Market Value (US$ Mn), By Type, 2022 – 2032

Table 9: North America Antibody Therapy Market Value (US$ Mn), By End-use, 2015 – 2021

Table 10: North America Antibody Therapy Market Value (US$ Mn), By End-use, 2022 – 2032

Table 11: North America Antibody Therapy Market, By Country, 2015 – 2021

Table 12: North America Antibody Therapy Market, By Country, 2022 – 2032

Table 13: Latin America Antibody Therapy Market Value (US$ Mn), By Type, 2015 – 2021

Table 14: Latin America Antibody Therapy Market Value (US$ Mn), By Type, 2022 – 2032

Table 15: Latin America Antibody Therapy Market Value (US$ Mn), By End-use, 2015 – 2021

Table 16: Latin America Antibody Therapy Market Value (US$ Mn), By End-use, 2022 – 2032

Table 17: Latin America Antibody Therapy Market, By Country, 2015 – 2021

Table 18: Latin America Antibody Therapy Market, By Country, 2022 – 2032

Table 19: Europe Antibody Therapy Market Value (US$ Mn), By Type, 2015 – 2021

Table 20: Europe Antibody Therapy Market Value (US$ Mn), By Type, 2022 – 2032

Table 21: Europe Antibody Therapy Market Value (US$ Mn), By End-use, 2015 – 2021

Table 22: Europe Antibody Therapy Market Value (US$ Mn), By End-use, 2022 – 2032

Table 23: Europe Antibody Therapy Market, By Country, 2015 – 2021

Table 24: Europe Antibody Therapy Market, By Country, 2022 – 2032

Table 25: Asia Pacific Antibody Therapy Market Value (US$ Mn), By Type, 2015 – 2021

Table 26: Asia Pacific Antibody Therapy Market Value (US$ Mn), By Type, 2022 – 2032

Table 27: Asia Pacific Antibody Therapy Market Value (US$ Mn), By End-use, 2015 – 2021

Table 28: Asia Pacific Antibody Therapy Market Value (US$ Mn), By End-use, 2022 – 2032

Table 29: Asia Pacific Antibody Therapy Market, By Country, 2015 – 2021

Table 30: Asia Pacific Antibody Therapy Market, By Country, 2022 – 2032

Table 31: MEA Antibody Therapy Market Value (US$ Mn), By Type, 2015 – 2021

Table 32: MEA Antibody Therapy Market Value (US$ Mn), By Type, 2022 – 2032

Table 33: MEA Antibody Therapy Market Value (US$ Mn), By End-use, 2015 – 2021

Table 34: MEA Antibody Therapy Market Value (US$ Mn), By End-use, 2022 – 2032

Table 35: MEA Antibody Therapy Market, By Country, 2015 – 2021

Table 36: MEA Antibody Therapy Market, By Country, 2022 – 2032

Table 37: Global Antibody Therapy Market Incremental $ Opportunity, By Type, 2015 - 2021

Table 38: Global Antibody Therapy Market Incremental $ Opportunity, By End-use, 2022 – 2032

Table 39: Global Antibody Therapy Market Incremental $ Opportunity, By Region, 2022 – 2032

Table 40: North America Antibody Therapy Market Incremental $ Opportunity, By Type, 2015 - 2021

Table 41: North America Antibody Therapy Market Incremental $ Opportunity, By End-use, 2022 – 2032

Table 42: North America Antibody Therapy Market Incremental $ Opportunity, By Country, 2022 – 2032

Table 43: Latin America Antibody Therapy Market Incremental $ Opportunity, By Type, 2015 - 2021

Table 44: Latin America Antibody Therapy Market Incremental $ Opportunity, By End-use, 2022 – 2032

Table 45: Latin America Antibody Therapy Market Incremental $ Opportunity, By Country, 2022 – 2032

Table 46: Europe Antibody Therapy Market Incremental $ Opportunity, By Type, 2015 - 2021

Table 47: Europe Antibody Therapy Market Incremental $ Opportunity, By End-use, 2022 – 2032

Table 48: Europe Antibody Therapy Market Incremental $ Opportunity, By Country, 2022 - 2032

Table 49: Asia Pacific Antibody Therapy Market Incremental $ Opportunity, By Type, 2015 - 2021

Table 50: Asia Pacific Antibody Therapy Market Incremental $ Opportunity, By End-use, 2022 – 2032

Table 51: Asia Pacific Antibody Therapy Market Incremental $ Opportunity, By Country, 2022 – 2032

Table 52: MEA Antibody Therapy Market Incremental $ Opportunity, By Type, 2015 - 2021

Table 53: MEA Antibody Therapy Market Incremental $ Opportunity, By End-use, 2022 – 2032

Table 54: MEA Antibody Therapy Market Incremental $ Opportunity, By Country, 2022 - 2032

Sabyasachi Ghosh
Principal Consultant
LinkedIn
Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Talk to Analyst
List of Charts

Figure 1: Global Antibody Therapy Market Value (US$ Mn) and Year-on-Year Growth, 2015-2032

Figure 2: Global Antibody Therapy Market Absolute $ Historical Gain (2015 - 2021) and Opportunity (2022 – 2032), US$ Mn

Figure 3: Global Antibody Therapy Market Share, By Type, 2022 & 2032

Figure 4: Global Antibody Therapy Market Y-o-Y Growth Projections, By Type – 2022-2032

Figure 5: Global Antibody Therapy Market Attractiveness Index, By Type – 2022-2032

Figure 6: Global Antibody Therapy Market Share, By End-use, 2022 & 2032

Figure 7: Global Antibody Therapy Market Y-o-Y Growth Projections, By End-use – 2022-2032

Figure 8: Global Antibody Therapy Market Attractiveness Index, By End-use – 2022-2032

Figure 9: Global Antibody Therapy Market Share, By Region, 2022 & 2032

Figure 10: Global Antibody Therapy Market Y-o-Y Growth Projections, By Region – 2022-2032

Figure 11: Global Antibody Therapy Market Attractiveness Index, By Region – 2022-2032

Figure 12: North America Antibody Therapy Market Value (US$ Mn) and Year-on-Year Growth, 2015-2032

Figure 13: North America Antibody Therapy Market Absolute $ Opportunity Historical (2015 - 2021) and Forecast Period (2022 – 2032), US$ Mn

Figure 14: North America Antibody Therapy Market Share, By Type, 2022 & 2032

Figure 15: North America Antibody Therapy Market Y-o-Y Growth Projections, By Type – 2022-2032

Figure 16: North America Antibody Therapy Market Attractiveness Index, By Type – 2022-2032

Figure 17: North America Antibody Therapy Market Share, By End-use, 2022 & 2032

Figure 18: North America Antibody Therapy Market Y-o-Y Growth Projections, By End-use – 2022-2032

Figure 19: North America Antibody Therapy Market Attractiveness Index, By End-use – 2022-2032

Figure 20: North America Antibody Therapy Market Share, By Country, 2022 & 2032

Figure 21: North America Antibody Therapy Market Y-o-Y Growth Projections, By Country – 2022-2032

Figure 22: North America Antibody Therapy Market Attractiveness Index, By Country – 2022-2032

Figure 23: Latin America Antibody Therapy Market Value (US$ Mn) and Year-on-Year Growth, 2015-2032

Figure 24: Latin America Antibody Therapy Market Absolute $ Opportunity Historical (2015 - 2021) and Forecast Period (2022 – 2032), US$ Mn

Figure 25: Latin America Antibody Therapy Market Share, By Type, 2022 & 2032

Figure 26: Latin America Antibody Therapy Market Y-o-Y Growth Projections, By Type – 2022-2032

Figure 27: Latin America Antibody Therapy Market Attractiveness Index, By Type – 2022-2032

Figure 28: Latin America Antibody Therapy Market Share, By End-use, 2022 & 2032

Figure 29: Latin America Antibody Therapy Market Y-o-Y Growth Projections, By End-use – 2022-2032

Figure 30: Latin America Antibody Therapy Market Attractiveness Index, By End-use – 2022-2032

Figure 31: Latin America Antibody Therapy Market Share, By Country, 2022 & 2032

Figure 32: Latin America Antibody Therapy Market Y-o-Y Growth Projections, By Country – 2022-2032

Figure 33: Latin America Antibody Therapy Market Attractiveness Index, By Country – 2022-2032

Figure 34: Europe Antibody Therapy Market Value (US$ Mn) and Year-on-Year Growth, 2015-2032

Figure 35: Europe Antibody Therapy Market Absolute $ Opportunity Historical (2015 - 2021) and Forecast Period (2022 – 2032), US$ Mn

Figure 36: Europe Antibody Therapy Market Share, By Type, 2022 & 2032

Figure 37: Europe Antibody Therapy Market Y-o-Y Growth Projections, By Type – 2022-2032

Figure 38: Europe Antibody Therapy Market Attractiveness Index, By Type – 2022-2032

Figure 39: Europe Antibody Therapy Market Share, By End-use, 2022 & 2032

Figure 40: Europe Antibody Therapy Market Y-o-Y Growth Projections, By End-use – 2022-2032

Figure 41: Europe Antibody Therapy Market Attractiveness Index, By End-use – 2022-2032

Figure 42: Europe Antibody Therapy Market Share, By Country, 2022 & 2032

Figure 43: Europe Antibody Therapy Market Y-o-Y Growth Projections, By Country – 2022-2032

Figure 44: Europe Antibody Therapy Market Attractiveness Index, By Country – 2022-2032

Figure 45: MEA Antibody Therapy Market Value (US$ Mn) and Year-on-Year Growth, 2015-2032

Figure 46: MEA Antibody Therapy Market Absolute $ Opportunity Historical (2015 - 2021) and Forecast Period (2022 – 2032), US$ Mn

Figure 47: MEA Antibody Therapy Market Share, By Type, 2022 & 2032

Figure 48: MEA Antibody Therapy Market Y-o-Y Growth Projections, By Type – 2022-2032

Figure 49: MEA Antibody Therapy Market Attractiveness Index, By Type – 2022-2032

Figure 50: MEA Antibody Therapy Market Share, By End-use, 2022 & 2032

Figure 51: MEA Antibody Therapy Market Y-o-Y Growth Projections, By End-use – 2022-2032

Figure 52: MEA Antibody Therapy Market Attractiveness Index, By End-use – 2022-2032

Figure 53: MEA Antibody Therapy Market Share, By Country, 2022 & 2032

Figure 54: MEA Antibody Therapy Market Y-o-Y Growth Projections, By Country – 2022-2032

Figure 55: MEA Antibody Therapy Market Attractiveness Index, By Country – 2022-2032

Figure 56: Asia Pacific Antibody Therapy Market Value (US$ Mn) and Year-on-Year Growth, 2015-2032

Figure 57: Asia Pacific Antibody Therapy Market Absolute $ Opportunity Historical (2015 - 2021) and Forecast Period (2022 – 2032), US$ Mn

Figure 58: Asia Pacific Antibody Therapy Market Share, By Type, 2022 & 2032

Figure 59: Asia Pacific Antibody Therapy Market Y-o-Y Growth Projections, By Type – 2022-2032

Figure 60: Asia Pacific Antibody Therapy Market Attractiveness Index, By Type – 2022-2032

Figure 61: Asia Pacific Antibody Therapy Market Share, By End-use, 2022 & 2032

Figure 62: Asia Pacific Antibody Therapy Market Y-o-Y Growth Projections, By End-use – 2022-2032

Figure 63: Asia Pacific Antibody Therapy Market Attractiveness Index, By End-use – 2022-2032

Figure 64: Asia Pacific Antibody Therapy Market Share, By Country, 2022 & 2032

Figure 65: Asia Pacific Antibody Therapy Market Y-o-Y Growth Projections, By Country – 2022-2032

Figure 66: Asia Pacific Antibody Therapy Market Attractiveness Index, By Country – 2022-2032

Figure 67: US Antibody Therapy Market Value (US$ Mn) and Forecast, 2022 - 2032

Figure 68: US Antibody Therapy Market Share, By Type, 2021

Figure 69: US Antibody Therapy Market Share, By End-use, 2021

Figure 70: Canada Antibody Therapy Market Value (US$ Mn) and Forecast, 2022 - 2032

Figure 71: Canada Antibody Therapy Market Share, By Type, 2021

Figure 72: Canada Antibody Therapy Market Share, By End-use, 2021

Figure 73: Brazil Antibody Therapy Market Value (US$ Mn) and Forecast, 2022 - 2032

Figure 74: Brazil Antibody Therapy Market Share, By Type, 2021

Figure 75: Brazil Antibody Therapy Market Share, By End-use, 2021

Figure 76: Mexico Antibody Therapy Market Value (US$ Mn) and Forecast, 2022 - 2032

Figure 77: Mexico Antibody Therapy Market Share, By Type, 2021

Figure 78: Mexico Antibody Therapy Market Share, By End-use, 2021

Figure 79: Germany Antibody Therapy Market Value (US$ Mn) and Forecast, 2022 - 2032

Figure 80: Germany Antibody Therapy Market Share, By Type, 2021

Figure 81: Germany Antibody Therapy Market Share, By End-use, 2021

Figure 82: U.K. Antibody Therapy Market Value (US$ Mn) and Forecast, 2022 - 2032

Figure 83: U.K. Antibody Therapy Market Share, By Type, 2021

Figure 84: U.K. Antibody Therapy Market Share, By End-use, 2021

Figure 85: France Antibody Therapy Market Value (US$ Mn) and Forecast, 2022 - 2032

Figure 86: France Antibody Therapy Market Share, By Type, 2021

Figure 87: France Antibody Therapy Market Share, By End-use, 2021

Figure 88: Italy Antibody Therapy Market Value (US$ Mn) and Forecast, 2022 - 2032

Figure 89: Italy Antibody Therapy Market Share, By Type, 2021

Figure 90: Italy Antibody Therapy Market Share, By End-use, 2021

Figure 91: BENELUX Antibody Therapy Market Value (US$ Mn) and Forecast, 2022 - 2032

Figure 92: BENELUX Antibody Therapy Market Share, By Type, 2021

Figure 93: BENELUX Antibody Therapy Market Share, By End-use, 2021

Figure 94: Nordic Countries Antibody Therapy Market Value (US$ Mn) and Forecast, 2022 - 2032

Figure 95: Nordic Countries Antibody Therapy Market Share, By Type, 2021

Figure 96: Nordic Countries Antibody Therapy Market Share, By End-use, 2021

Figure 97: China Antibody Therapy Market Value (US$ Mn) and Forecast, 2022 - 2032

Figure 98: China Antibody Therapy Market Share, By Type, 2021

Figure 99: China Antibody Therapy Market Share, By End-use, 2021

Figure 100: Japan Antibody Therapy Market Value (US$ Mn) and Forecast, 2022 - 2032

Figure 101: Japan Antibody Therapy Market Share, By Type, 2021

Figure 102: Japan Antibody Therapy Market Share, By End-use, 2021

Figure 103: South Korea Antibody Therapy Market Value (US$ Mn) and Forecast, 2022 - 2032

Figure 104: South Korea Antibody Therapy Market Share, By Type, 2021

Figure 105: South Korea Antibody Therapy Market Share, By End-use, 2021

Figure 106: GCC Countries Antibody Therapy Market Value (US$ Mn) and Forecast, 2022 - 2032

Figure 107: GCC Countries Antibody Therapy Market Share, By Type, 2021

Figure 108: GCC Countries Antibody Therapy Market Share, By End-use, 2021

Figure 109: South Africa Antibody Therapy Market Value (US$ Mn) and Forecast, 2022 - 2032

Figure 110: South Africa Antibody Therapy Market Share, By Type, 2021

Figure 111: South Africa Antibody Therapy Market Share, By End-use, 2021

Figure 112: Turkey Antibody Therapy Market Value (US$ Mn) and Forecast, 2022 - 2032

Figure 113: Turkey Antibody Therapy Market Share, By Type, 2021

Figure 114: Turkey Antibody Therapy Market Share, By End-use, 2021

Need specific information?

Request Customization

Explore Healthcare Insights

View Reports
Google translate

Antibody Therapy Market